MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
45.56
+0.62
+1.38%
After Hours: 47.95 +2.39 +5.25% 17:58 12/15 EST
OPEN
45.74
PREV CLOSE
44.94
HIGH
46.38
LOW
43.92
VOLUME
430.75K
TURNOVER
--
52 WEEK HIGH
47.86
52 WEEK LOW
12.21
MARKET CAP
1.26B
P/E (TTM)
-16.1641
1D
5D
1M
3M
1Y
5Y
1D
VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026
Reuters · 18h ago
VANDA ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE FDA FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS
Reuters · 18h ago
Weekly Report: what happened at ANAB last week (1208-1212)?
Weekly Report · 19h ago
AnaptysBio Is Maintained at Buy by Stifel
Dow Jones · 4d ago
AnaptysBio Price Target Cut to $56.00/Share From $80.00 by Stifel
Dow Jones · 4d ago
Stifel Maintains Buy on AnaptysBio, Lowers Price Target to $56
Benzinga · 4d ago
AnaptysBio price target lowered to $56 from $80 at Stifel
TipRanks · 4d ago
ANAPTYSBIO INC <ANAB.O>: STIFEL CUTS TARGET PRICE TO $56 FROM $80
Reuters · 4d ago
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.